Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Wellcome Trust has awarded a two-year extension to the grant for our Wellcome Centre for Integrative Neuroimaging. This means that WIN is funded through to April 2024.

Group of researchers from Wellcome Centre for Integrative Neuroimaging

The Wellcome Centre for Integrative Neuroimaging (WIN) was established in 2017. It bridges the gap between laboratory neuroscience and human health, by performing multi-scale studies spanning from animal models through to human populations.

The extension is testament to the progress that WIN has demonstrated so far against its vision in all five of its themes: cross-species relationships; cross-scale integration; population data-mining; clinical neuroimaging and open neuroimaging.

WIN researchers have so far generated 698 peer-reviewed publications (and 152 preprints). These papers have collectively gathered 4807 citations to date.

The work of WIN staff has had an impact in many areas, including:

  • Clinical discovery (e.g. throuh the licensing of its software library (FSL) to non-academic users in clinical settings)
  • Clinical practice (e.g. establishing the ‘Brain Health Centre’, opening to memory clinic patients in spring 2020)
  • Engaging industry (e.g. hosting five industry-funded PhD students)
  • Scientific practice: (e.g. influencing neuroimaging research practice via FSL. The main FSL paper has been cited >9000 times).
  • Public debate (e.g. holding a day for patients and public on ‘Building better brain research’).

WIN has also had an impact more locally, initiating new collaborations and leveraging further funding. Fifty-three PhD students have completed since WIN began, and facilities have been enhanced (including the installation of a new rodent scanner and a new MEG scanner).

WIN has ensured that working practices reflect its values, including openness and inclusivity. For example, they have established working groups in Open Science and Equality, Diversity and Inclusion.

Core staff have been recruited, including Jason Lerch (heading up the small-animal imaging facility), Ben Seymour (Wellcome Clinical Research Fellow) and Madalena Fonseca (preclinical functional MRI).

The extension will allow WIN to establish incentives (e.g seed grants) and support (e.g facilitators) for projects that take mechanism to clinical population, or basic neuroscience to clinical translation. It will also provide resources to develop their cutting-edge work on building a positive research culture.

Similar stories

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Royal Academy of Engineering Research Fellowship

Dr Rezvan Farahibozorg has received one of 17 Royal Academy of Engineering Research Fellowships for 2022.

Three New Professors

Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.

Insights into the molecular pathways of progressive multiple sclerosis

Text by Ian Fyfe for 'Nature Reviews Neurology'